Janux Therapeutics (JANX) Total Current Liabilities (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of Total Current Liabilities data on file, last reported at $58.9 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 236.62% year-over-year to $58.9 million in Q1 2026; TTM through Mar 2026 was $58.9 million, a 236.62% increase from a year earlier, with the FY2025 full-year figure at $25.0 million, up 43.18% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $58.9 million, up from $25.0 million in the prior quarter.
• Over the last five years, Total Current Liabilities for JANX reached as high as $58.9 million in Q1 2026 and fell as low as $10.6 million in Q1 2024.
• Historically, Total Current Liabilities has averaged $19.3 million across 5 years, with a median of $16.5 million in 2022.
• Across the five-year window, Total Current Liabilities slumped 35.52% in 2024 and surged 236.62% in 2026, its largest moves.
• Year by year, Total Current Liabilities stood at $16.5 million in 2022, then dropped by 21.05% to $13.0 million in 2023, then soared by 33.96% to $17.5 million in 2024, then soared by 43.18% to $25.0 million in 2025, then surged by 135.69% to $58.9 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $58.9 million in Q1 2026, $25.0 million in Q4 2025, and $27.8 million in Q3 2025.